Stockreport

Immuneering rises on orphan drug designation for treatment of pancreatic cancer [Seeking Alpha]

Immuneering Corporation - Class A  (IMRX) 
PDF FDA has granted orphan drug designation to IMM-1-104 in the treatment of pancreatic cancer. IMM-1-104 is currently being evaluated in a Phase 2a clinical trial in pati [Read more]